{
  "drug_id": "D005",
  "drug_name": "Erythron",
  "indication": "Hematology-B",
  "modality": "small molecule",
  "mechanism": "ligand neutralizing antibody",
  "moa_short": "Neutralizes a circulating ligand to reduce pathway activation.",
  "formulation": "tablet",
  "route": "oral",
  "regimen": "50 mg QD",
  "trial_id": "AMGN-D005-302",
  "phase": "Phase 3",
  "arms": [
    {
      "name": "Erythron 50 mg QD",
      "n": 238,
      "dose": "50 mg QD"
    },
    {
      "name": "Placebo",
      "n": 227,
      "dose": "matching regimen"
    }
  ],
  "population": "Adults with moderate-to-severe Hematology-B with inadequate response to standard therapy.",
  "key_inclusion": [
    "Confirmed diagnosis per protocol definition",
    "Baseline disease activity above threshold",
    "Stable background therapy for \u22654 weeks"
  ],
  "key_exclusion": [
    "Severe uncontrolled comorbidity (per protocol)",
    "Recent major surgery within 12 weeks",
    "Known hypersensitivity to components"
  ],
  "results": {
    "endpoint_primary": "Change from baseline in Symptom Score at Week 12",
    "endpoint_secondary": "Durable response at Week 24",
    "primary_effect": "LS mean difference -2.06 (Drug \u2212 Placebo)",
    "primary_pvalue": 0.0013769700187049629,
    "primary_ci": "[-2.46, -1.66]",
    "secondary_effect": "Did not meet prespecified significance threshold",
    "discontinuation_rate_pct": 4.4529474947378835
  },
  "safety": {
    "common_ae": [
      [
        "Arthralgia",
        18.134408484443277
      ],
      [
        "Rash",
        16.309853220028923
      ],
      [
        "Fatigue",
        16.218173032735592
      ],
      [
        "Elevated ALT",
        13.663236625833935
      ],
      [
        "Upper respiratory infection",
        12.141974286566574
      ],
      [
        "Dizziness",
        9.03128828639429
      ]
    ],
    "serious_ae_rate_pct": 4.836829594359973,
    "discontinuation_ae_rate_pct": 5.030392923928337,
    "warnings": [
      "Monitor for hypersensitivity reactions.",
      "Assess for infection risk in susceptible patients.",
      "Consider hepatic monitoring if clinically indicated."
    ],
    "contraindications": [
      "Known hypersensitivity to active substance or excipients."
    ]
  },
  "monitoring": [
    "Baseline labs per protocol (CBC, CMP)",
    "Periodic assessment of liver enzymes",
    "Clinical monitoring for infections"
  ],
  "version": "v2.3",
  "doc_date": "2025-12-26"
}